Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was down 4.7% on Tuesday . The stock traded as low as $9.84 and last traded at $9.75. Approximately 1,159 shares traded hands during mid-day trading, a decline of 81% from the average daily volume of 6,180 shares. The stock had previously closed at $10.23.
Pharming Group Stock Performance
The company has a market capitalization of $687.91 million, a price-to-earnings ratio of -50.20 and a beta of 0.02. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.00 and a current ratio of 2.76. The firm has a 50-day simple moving average of $10.62 and a two-hundred day simple moving average of $9.43.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative return on equity of 6.01% and a negative net margin of 4.14%. The company had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. On average, sell-side analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
Institutional Investors Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 52,147 shares of the company's stock after acquiring an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
